Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SWATH-MS analysis of cerebrospinal fluid to generate a robust battery of biomarkers for Alzheimer's disease.

Scientific reports - 4 May 2020

Park Sun Ah, Jung Jin Myung, Park Jun Sung, Lee Jeong Ho, Park Bumhee, Kim Hyung Jun, Park Jeong-Ho, Chae Won Seok, Jeong Jee Hyang, Choi Seong Hye, Baek Je-Hyun

Abstract excerpt

Cerebrospinal fluid (CSF) Aβ42 and tau protein levels are established diagnostic biomarkers of Alzheimer's disease (AD). However, their inadequacy to represent clinical efficacy in drug trials indicates the need for new biomarkers. Sequential window acquisition of all theoretical fragment ion spectra (SWATH)-based mass spectrometry (MS) is an advanced proteomic tool for large-scale, high-quality quantification....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Data Mining

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dementia

Share to Mass Spectrometry

Share to Peptide Fragments

Share to Proteomics

Share to Reference Values

Share to tau Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 32366888
DOI: 10.1038/s41598-020-64461-y
PMCID: PMC7198522

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SWATH-MS analysis of cerebrospinal fluid to generate a robust battery of biomarkers for Alzheimer's disease.PMID 32366888Read ↗

SWATH Mass Spectrometry-Based CSF Proteome Profile of GBA-Linked Parkinson’s Disease PatientsSemantic proximity Read ↗

Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's diseaseSemantic proximity Read ↗

Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s diseaseSemantic proximity Read ↗

Proteomic Subtyping of Alzheimer’s Disease CSF links Blood-Brain Barrier Dysfunction to Reduced levels of Tau and Synaptic BiomarkersSemantic proximity Read ↗

Large-scale cerebrospinal fluid proteomic analysis in Alzheimer’s disease patients reveals five molecular subtypes with distinct genetic risk profilesSemantic proximity Read ↗

Systematic proteomics in Autosomal dominant Alzheimer’s disease reveals decades-early changes of CSF proteins in neuronal death, and immune pathwaysSemantic proximity Read ↗

CSF proteomics identifies early changes in autosomal dominant Alzheimer's disease.Semantic proximity Read ↗

Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease.Semantic proximity Read ↗

Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profilesSemantic proximity Read ↗

Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseasesSemantic proximity Read ↗

Proteomics of brain, CSF, and plasma identifies molecular signatures for distinguishing sporadic and genetic Alzheimer’s diseaseSemantic proximity Read ↗

Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.